136.65
-1.12 (-0.81%)
| Penutupan Terdahulu | 137.77 |
| Buka | 136.07 |
| Jumlah Dagangan | 1,408,204 |
| Purata Dagangan (3B) | 2,061,295 |
| Modal Pasaran | 11,910,505,472 |
| Harga / Buku (P/B) | 24.35 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -4,865.98% |
| EPS Cair (TTM) | -3.45 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -17.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 269.12% |
| Nisbah Semasa (MRQ) | 1.25 |
| Aliran Tunai Operasi (OCF TTM) | -152.60 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -87.22 M |
| Pulangan Atas Aset (ROA TTM) | -48.60% |
| Pulangan Atas Ekuiti (ROE TTM) | -196.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Abivax SA | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.83 |
|
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Institusi | 50.19% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Darwin Global Management, Ltd. | 31 Mar 2026 | 3,468,657 |
| Helikon Investments Ltd | 31 Mar 2026 | 1,013,324 |
| Lord, Abbett & Co. Llc | 31 Mar 2026 | 854,920 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |